Phase II study of pibenzimol in pancreatic cancer. A Southwest Oncology Group study
| Autor: | Brent C. Behrens, James A. Neidhart, John S. Macdonald, Eric H. Kraut, Mark Segal, Thomas R. Fleming |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Oncology
Adult medicine.medical_specialty Pancreatic disease medicine.medical_treatment Phases of clinical research Adenocarcinoma Internal medicine Pancreatic cancer medicine Humans Pharmacology (medical) Aged Pharmacology Chemotherapy Group study business.industry Middle Aged medicine.disease Pancreatic Neoplasms medicine.anatomical_structure Toxicity Bisbenzimidazole Drug Evaluation business Pancreas |
| Zdroj: | Investigational new drugs. 9(1) |
| ISSN: | 0167-6997 |
| Popis: | Twenty-three patients with advanced pancreatic adenocarcinoma were treated with Pibenzimol utilizing a daily intravenous schedule for five days. There were no objective responses seen. The major toxicity was pancreatic with grade 3 hyperglycemia in eleven patients. Pibenzimol is inactive in patients with advanced pancreatic adenocarcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink